Samyang, Access Pharmaceuticals Ink RNAi-Delivery Research Deals
April 14, 2011
Samyang, Access Pharmaceuticals Ink RNAi-Delivery Research Deals
The deals suggest that big pharma remains interested in the gene-silencing technology despite recent pullbacks in the sector, which have raised concerns among industry watchers.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
December 9, 2010 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - With Primate Testing on Deck, nLife Aims at Partnerships for Neuron Delivery Technology
February 28, 2013 / Gene Silencing News - RNAi Drug Delivery Startup Solstice Closes $18M Series Financing Round
January 10, 2013 / Gene Silencing News - Cenix Partners with US Non-Profit on Rare Disease Research
September 27, 2012 / Gene Silencing News